Biological response of B lymphoma cell lines to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated lysis.

被引：0
|
作者：
Golay, J
Zaffaroni, L
Vaccari, T
Borleri, GM
Tedesco, F
Dastoli, G
Barbui, T
Rambaldi, A
Introna, M
机构：
[1] Ist Ric Farmacol Mario Negri, Milan, Italy
[2] Osped Riuniti Bergamo, Div Hematol, I-24100 Bergamo, Italy
[3] Roche Italia, Milan, Italy
[4] Univ Trieste, Trieste, Italy
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
401
引用
收藏
页码：92A / 92A
页数：1
相关论文
共 50 条
  • [1] Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
    Golay, J
    Zaffaroni, L
    Vaccari, T
    Lazzari, M
    Borleri, GM
    Bernasconi, S
    Tedesco, F
    Rambaldi, A
    Introna, M
    [J]. BLOOD, 2000, 95 (12) : 3900 - 3908
  • [2] Fludarabine synergises with anti CD20 monoclonal antibody Rituximab in complement mediated cell lysis.
    Golay, J
    Xiao, YM
    Di Gaetano, N
    Dastoli, G
    Rambaldi, A
    Introna, M
    [J]. BLOOD, 2000, 96 (11) : 339A - 339A
  • [3] Expression of complement inhibitors CD46, CD55 and CD59 and response to rituximab in patients with CD20+ non hodgkins lymphoma
    Dzietczenia, J.
    Wrobel, T.
    Mazur, G.
    Biedron, M.
    Jazwiec, B.
    Kuliczkowski, K.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 533 - 533
  • [4] Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
    Takei, K
    Yamazaki, T
    Sawada, U
    Ishizuka, H
    Aizawa, S
    [J]. LEUKEMIA RESEARCH, 2006, 30 (05) : 625 - 631
  • [5] CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
    Golay, J
    Lazzari, M
    Facchinetti, V
    Bernasconi, S
    Borleri, G
    Barbui, T
    Rambaldi, A
    Introna, M
    [J]. BLOOD, 2001, 98 (12) : 3383 - 3389
  • [6] Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20(+) non-Hodgkin’s lymphoma
    Justyna Dzietczenia
    Tomasz Wróbel
    Grzegorz Mazur
    Rafał Poręba
    Bożena Jaźwiec
    Kazimierz Kuliczkowski
    [J]. Medical Oncology, 2010, 27 : 743 - 746
  • [7] Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20(+) non-Hodgkin's lymphoma
    Dzietczenia, Justyna
    Wrobel, Tomasz
    Mazur, Grzegorz
    Poreba, Rafal
    Jazwiec, Bozena
    Kuliczkowski, Kazimierz
    [J]. MEDICAL ONCOLOGY, 2010, 27 (03) : 743 - 746
  • [8] Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59
    Clayton, A
    Harris, CL
    Court, J
    Mason, MD
    Morgan, BP
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (02) : 522 - 531
  • [9] EXPRESSION OF THE COMPLEMENT REGULATORY PROTEINS CD21, CD55 AND CD59 ON BURKITT-LYMPHOMA LINES - THEIR ROLE IN SENSITIVITY TO HUMAN SERUM-MEDIATED LYSIS
    KURAYA, M
    YEFENOF, E
    KLEIN, G
    KLEIN, E
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (07) : 1871 - 1876
  • [10] The susceptibility of freshly isolated B-non Hodgkin lymphoma cells to Rituximab and complement is determined by CD20 levels and the CD55/CD59 inhibitors.
    Golay, J
    Lazzari, M
    Facchinetti, V
    Borleri, G
    Dastoli, G
    Barbui, T
    Introna, M
    Rambaldi, A
    [J]. BLOOD, 2000, 96 (11) : 338A - 338A
12345